2020-11-10
Hydrogen water research achieves better results
The latest research from Qian Liren's research group from the Department of Hematology, the Sixth Medical Center of the PLA General Hospital, proves that drinking hydrogen water (4 ml/kg body weight) 3 times a day can effectively treat cGVHD Chronic graft versus host disease (cGVHD) is the main cause of non-transplant death after allogeneic hematopoietic stem cell transplantation. At present, the first-line treatment is glucocorticoids, but there is no standard treatment for patients who are refractory or dependent on corticosteroid therapy. Considering that a large number of studies have shown that hydrogen has an anti-inflammatory effect, has a certain preventive effect on rejection after organ transplantation, and the side effects of hydrogen are small, the researchers speculate that hydrogen may have a therapeutic effect on patients with cGVHD. To prove this speculation, the researchers conducted a prospective open phase 2 hydrogen medicine study. The patient took 4ml/kg hydrogen-rich water orally three times a day. The reactions of the skin, mouth, gastrointestinal (GI), liver, eyes, lungs, joints and fascia are graded every 3 months. A total of 24 patients (median age 27 years) were included in the study. Of the 24 patients, 18 (75%; 95% CI, 55.1% to 88%) had an objective response. No obvious toxicity was observed in all subjects. The estimated 4-year overall survival rate was 74.7% (95% CI, 54.9%-94.5%). The survival time of the response group was significantly prolonged. The 4-year survival rate of the response group was significantly higher than that of the non-response group (86.6% vs 0%; p= 0.000132). Hydrogen not only has a significant effect on cGVHD patients, but also has no obvious side effects from long-term use of hydrogen.
View More